Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report
- Author:
Cheol Kyu PARK
1
;
Jae Young HUR
;
Chang Min CHOI
;
Tae Ok KIM
;
Hyun Ju CHO
;
Hong Joon SHIN
;
Jung Hwan LIM
;
Yoo Duk CHOI
;
Young Chul KIM
;
In Jae OH
Author Information
- Publication Type:Case Report
- Keywords: HER2 mutation; Non-small Cell Lung Cancer; Afatinib
- MeSH: Asian Continental Ancestry Group; Carcinoma, Non-Small-Cell Lung; Drug Therapy; Exons; Female; Humans; Middle Aged; Receptor, Epidermal Growth Factor
- From:Journal of Korean Medical Science 2018;33(1):e7-
- CountryRepublic of Korea
- Language:English
- Abstract: Human epidermal growth factor receptor 2 (HER2) mutation in non-small cell lung cancer (NSCLC) is an oncogenic driver that possibly becomes a druggable target to HER2-targeted therapy. The benefit of HER2-targeted therapy is much less defined especially in eastern populations. We provide evidence of clinical benefit of afatinib in a 50-year-old Asian woman with HER2-mutant NSCLC who previously failed cytotoxic chemotherapy and gefitinib treatment. Next-generation sequencing of the tumor tissue revealed a HER2 exon 20 mutation (c.2437A > G), which has never been reported. The patient was treated with afatinib for more than four months. She showed rapid radiologic response within a month, and maintained stable state until the last dose of afatinib.
